利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.024 秒)

    Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
    2.
    发明授权
    Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides 失效
    增强成纤维细胞生长因子受体5多肽免疫应答的方法

    公开(公告)号：US07083791B2

    公开(公告)日：2006-08-01

    申请号：US10613413

    申请日：2003-07-03

    申请人： Matthew Sleeman ,  J. Greg Murison

    发明人： Matthew Sleeman ,  J. Greg Murison

    IPC分类号： A61K38/00 ,  A61K38/16 ,  C07K14/00

    CPC分类号： C07K14/71 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/47 ,  C07K14/715 ,  C07K16/2863 ,  C07K2319/00

    摘要： Isolated fibroblast growth factor receptor (FGFR5) polypeptides and polynucleotides encoding such polypeptides are provided. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to and agonize or antagonize FGFR5 polypeptide function. Specific binding molecules include antibodies, functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5 and, thus, are effective agents suitable for the treatment of diseases such as osteopontin-mediated autoimmune disease, such as systemic lupus erythematosus, bone disorders including osteoporosis and osteopetrosis, and cancers, including cellular carcinomas such as hepatocellular carcinomas.

    摘要翻译： 提供分离的成纤维细胞生长因子受体（FGFR5）多肽和编码这些多肽的多核苷酸。 还提供了FGFR5基因表达的调节剂和特异性结合并激动或拮抗FGFR5多肽功能的结合分子。 特异性结合分子包括抗体，其功能片段，以及特异性结合FGFR5的scFv和骆驼科重链IgG，从而调节FGFR5的活性，因此是适合于治疗疾病如骨桥蛋白介导的自身免疫疾病 ，例如系统性红斑狼疮，包括骨质疏松症和骨硬化的骨病，和癌症，包括细胞癌如肝细胞癌。

    Fibroblast growth factor receptors and methods for their use
    3.
    发明申请
    Fibroblast growth factor receptors and methods for their use 审中-公开
    成纤维细胞生长因子受体及其使用方法

    公开(公告)号：US20060115483A1

    公开(公告)日：2006-06-01

    申请号：US11154977

    申请日：2005-06-15

    申请人： Matthew Sleeman ,  J. Murison ,  Zhihui Cao

    发明人： Matthew Sleeman ,  J. Murison ,  Zhihui Cao

    IPC分类号： C07K14/82 ,  C07K16/30 ,  C07H21/04 ,  C12P21/06 ,  A61K39/395

    CPC分类号： C07K16/2863 ,  C07K14/71 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/30

    摘要： Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.

    摘要翻译： 分离的成纤维细胞生长因子受体5（FGFR5）多肽与编码这种多肽的多核苷酸一起提供。 还提供了FGFR5基因表达的调节剂和特异性结合并激动或拮抗FGFR5多肽功能的结合分子。 结合分子包括抗体及其功能片段，以及特异性结合FGFR5的scFv和骆驼科重链IgG，从而调节FGFR5的活性。 FGFR5基因表达的这种结合剂和调节剂可用于治疗疾病，包括：骨桥蛋白介导的疾病; 自身免疫性疾病，如系统性红斑狼疮; 骨质疏松症和骨硬化等骨质疏松症; 和癌症，包括细胞癌如肝细胞癌。

    Fibroblast growth factor receptors and methods for their use
    4.
    发明申请
    Fibroblast growth factor receptors and methods for their use 审中-公开
    成纤维细胞生长因子受体及其使用方法

    公开(公告)号：US20050112642A1

    公开(公告)日：2005-05-26

    申请号：US10954094

    申请日：2004-09-29

    申请人： Matthew Sleeman ,  J. Murison ,  Zhihui Cao

    发明人： Matthew Sleeman ,  J. Murison ,  Zhihui Cao

    IPC分类号： A61K38/00 ,  C07H21/04 ,  C07K14/71 ,  C07K16/28 ,  C12Q1/68

    CPC分类号： C07H21/04 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/2863 ,  C07K2319/00

    摘要： Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.

    摘要翻译： 分离的成纤维细胞生长因子受体5（FGFR5）多肽与编码这种多肽的多核苷酸一起提供。 还提供了FGFR5基因表达的调节剂和特异性结合并激动或拮抗FGFR5多肽功能的结合分子。 结合分子包括抗体及其功能片段，以及特异性结合FGFR5的scFv和骆驼科重链IgG，从而调节FGFR5的活性。 FGFR5基因表达的这种结合剂和调节剂可用于治疗疾病，包括：骨桥蛋白介导的疾病; 自身免疫性疾病，如系统性红斑狼疮; 骨质疏松症和骨硬化等骨质疏松症; 和癌症，包括细胞癌如肝细胞癌。

    Fibroblast growth factor receptors and methods for their use
    7.
    发明申请
    Fibroblast growth factor receptors and methods for their use 审中-公开

    公开(公告)号：US20050009750A1

    公开(公告)日：2005-01-13

    申请号：US10885225

    申请日：2004-07-06

    申请人： Matthew Sleeman ,  J. Murison ,  Zhihui Cao

    发明人： Matthew Sleeman ,  J. Murison ,  Zhihui Cao

    IPC分类号： C07H21/04 ,  C07K14/71 ,  A61K38/17

    CPC分类号： C07K14/71 ,  C07H21/04

    摘要： Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.